ADC Therapeutics stock sets two November investor events
Published on 11/04/2026 at 03:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUpcoming catalysts for ADC Therapeutics
- Management will present at the Guggenheim Healthcare Innovation Conference on November 10.
- A second investor presentation is scheduled for the Jefferies Global Healthcare Conference on November 19.
- Third-quarter 2026 results are due by press release on November 9.
ADC Therapeutics will take part in two November investor conferences, giving shareholders fresh dates for management commentary before the company's third-quarter results. The announcement was reported by PR Newswire via Fidelity on Tuesday, November 3, 2026.
Two November investor presentations
Chief Executive Officer Ameet Mallik is scheduled to take part in a fireside chat at the Guggenheim Third Annual Healthcare Innovation Conference in Boston on Tuesday, November 10, at 1:30 p.m. Eastern Time.
ADC Therapeutics will then appear at the Jefferies Global Healthcare Conference in London on Thursday, November 19. The presentation is scheduled for 1:00 to 1:25 p.m. Greenwich Mean Time. Live webcasts and replays of both events will be available through the company's investor-relations website.
Results provide the next checkpoint
The company said on November 2 that it will release its full third-quarter 2026 financial results on Monday, November 9. The release gives investors the next scheduled checkpoint for ZYNLONTA sales, operating expenses, liquidity and development priorities.
ADC Therapeutics' investor materials continue to highlight regulatory and clinical uncertainty around ZYNLONTA, including the LOTIS-5 program and the LOTIS-7 combination with glofitamab. The November presentations may therefore focus attention on regulatory plans, clinical milestones and the resources available to advance the pipeline.
ADC Therapeutics' business focus
ADC Therapeutics develops antibody-drug conjugates designed to deliver targeted cancer treatments. Its commercial portfolio is centered on ZYNLONTA, or loncastuximab tesirine-lpyl, which has accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for certain patients with relapsed or refractory diffuse large B-cell lymphoma.
The company is headquartered in Lausanne, Switzerland, and has operations in New Jersey. Its activities span clinical development, manufacturing and commercialization, with additional work on combinations and earlier treatment lines.
ADC Therapeutics at a glance
- Company: ADC Therapeutics SA
- ISIN: CH0499880968
- Ticker: ADCT
- Exchange: New York Stock Exchange
- Headquarters: Lausanne, Switzerland
The Swiss Market Index provides broader market context for Swiss-listed companies; current market coverage is available here.
